Juposci 5 mg colourless syrup

JUPOSCI is used in the treatment of conditions associated with gastrointestinal spasm.

Posology: The initial oral dose must be the lowest recommended for age. Children older than 1 year up to 3 years: 5 to 10 ml three times daily. Children older than 3 years up to 6 years: 10 ml three times daily. Children older than 6 years up to 12 years: 10 to 20 ml three times daily. Children older than 12 years and adults: 20 ml four times daily. Paediatric population: Babies older than 1 month up to 3 months: 2, 5 ml three times daily. Infants older than 3 months up to 1 year: 2, 5 to 5 ml three times daily.

JUPOSCI should not be used in patients with:

• Myasthenia gravis
• Closed angle glaucoma
• Narrow angle between the iris and the cornea with a high ambient temperature, especially in children
• Porphyria
• Intestinal obstruction or ileus.

JUPOSCI should not be used in patients who have experienced prior hypersensitivity to hyoscine butylbromide. Hyoscine butylbromide is contraindicated in patients who have tachycardia, hypotension, anaphylaxis and cardiac diseases or history of cardiac disease or hypertension. JUPOSCI should not be used during pregnancy and lactation.

DO NOT EXCEED THE PRESCRIBED DOSE. JUPOSCI should be used with care in the following;

General disorders:

• Fever

Cardiac disorders:

• tachycardia
• myocardial infarction

Gastrointestinal disorders:

• paralytic ileus
• pyloric stenosis
• ulcerative colitis
• exacerbate reflux
• diarrhoea

Renal and urinary disorders:

• prostatic enlargement
• impaired kidney function

Disorders of metabolism:

• impaired metabolic function

Vascular disorders:

• hypertension

Hepato-biliary disorders:

• impaired liver function

Contains glycerol and sorbitol and may have a laxative effect. Patient with the rare hereditary condition of sorbitol intolerance should not take JUPOSCI.

The effects of JUPOSCI may be enhanced by the concomitant administration of other medicines with antimuscarinic properties, such as amantadine, some antihistamines, butyrophenones, phenothiazines and tricyclic antidepressants. The absorption of other medicines may also be affected due to the reduction in gastric motility.

JUPOSCI should not be used during pregnancy and lactation.

The effect on the ability to drive and use machine has not been established.

Frequency System organ class Undesirable effects Less frequent Cardiac disorders u2022 Transient bradycardia u2022 Tachycardia u2022 Palpitations, arrhythmias General disorders u2022 Dryness of the mouth u2022 Difficulty in swallowing and talking u2022 Thirst Skin disorders and subcutaneous tissue disorders u2022 Flushing u2022 Dryness of the skin Renal and urinary disorders u2022 Difficulty micturition Frequency not known Gastrointestinal disorders u2022 Reduction in the tone u2022 Motility of the gastrointestinal tract leading to constipation. Eye disorders u2022 Mydriasis (Dilatation of the pupils) u2022 Cyclopegia (Loss in accommodation) u2022 Photophobia Respiratory disorders u2022 Reduced bronchial secretions

In toxic doses anticholinergic effects predominate. These include tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations and delirium. A flushing of the face and upper trunk may be a prominent feature. Overdose may cause postural hypotension. Toxic doses may cause non-depolarising neuromuscular block. Treatment is symptomatic and supportive.